Health
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
- Government adds $72 million to series of awards for shots
- HHS aims to have 10 million shots on hand by early 2025
Photographer: Liesa Johannssen-Koppitz/Bloomberg
This article is for subscribers only.
GSK Plc, Sanofi and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human infections that have raised concerns about further spread.
The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising the country’s total supply of ready-to-use doses to 10 million within the first quarter of 2025, Dawn O’Connell, the Department of Health and Human Services’ assistant secretary for preparedness and response, said in an interview with Bloomberg News.